<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">479913</article-id><article-id pub-id-type="doi">10.17816/onco479913</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of the incidence of lung cancer in the Krasnoyarsk Territory. Justification of the Introduction of innovative methods of early diagnosis</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ заболеваемости раком лёгкого в Красноярском крае. Обоснование внедрения инновационных методов ранней диагностики</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7210-3020</contrib-id><contrib-id contrib-id-type="spin">3632-8415</contrib-id><name-alternatives><name xml:lang="en"><surname>Zukov</surname><given-names>Ruslan A.</given-names></name><name xml:lang="ru"><surname>Зуков</surname><given-names>Руслан Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>zukov_rus@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8177-6788</contrib-id><contrib-id contrib-id-type="spin">1548-5565</contrib-id><name-alternatives><name xml:lang="en"><surname>Safontsev</surname><given-names>Ivan P.</given-names></name><name xml:lang="ru"><surname>Сафонцев</surname><given-names>Иван Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>safoncev@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7849-0770</contrib-id><contrib-id contrib-id-type="spin">7179-8793</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimenok</surname><given-names>Marina P.</given-names></name><name xml:lang="ru"><surname>Клименок</surname><given-names>Марина Петровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>klimenok71@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4987-5222</contrib-id><contrib-id contrib-id-type="spin">8365-3582</contrib-id><name-alternatives><name xml:lang="en"><surname>Zabrodskaya</surname><given-names>Tatyana E.</given-names></name><name xml:lang="ru"><surname>Забродская</surname><given-names>Татьяна Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>zabrodskayate@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-5357-2637</contrib-id><contrib-id contrib-id-type="spin">2846-8592</contrib-id><name-alternatives><name xml:lang="en"><surname>Krat</surname><given-names>Aleksey V.</given-names></name><name xml:lang="ru"><surname>Крат</surname><given-names>Алексей Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>kratAV@onkolog24.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1054-4629</contrib-id><contrib-id contrib-id-type="spin">5387-9071</contrib-id><name-alternatives><name xml:lang="en"><surname>Kichkailo</surname><given-names>Anna S.</given-names></name><name xml:lang="ru"><surname>Кичкайло</surname><given-names>Анна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Bio)</p></bio><bio xml:lang="ru"><p>д-р биол. наук</p></bio><email>annazamay@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7493-8742</contrib-id><contrib-id contrib-id-type="spin">8799-8497</contrib-id><name-alternatives><name xml:lang="en"><surname>Zamay</surname><given-names>Tatyana N.</given-names></name><name xml:lang="ru"><surname>Замай</surname><given-names>Татьяна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Bio), Assistant Professor</p></bio><bio xml:lang="ru"><p>д-р биол. наук, доцент</p></bio><email>zamay@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University</institution></aff><aff><institution xml:lang="ru">Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovsky</institution></aff><aff><institution xml:lang="ru">Красноярский краевой клинический онкологический диспансер имени А.И. Крыжановского</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-12-17" publication-format="electronic"><day>17</day><month>12</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-11-27" publication-format="electronic"><day>27</day><month>11</month><year>2022</year></pub-date><volume>27</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>171</fpage><lpage>181</lpage><history><date date-type="received" iso-8601-date="2023-06-07"><day>07</day><month>06</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-04"><day>04</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Эко-Вектор</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-11-27"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/479913">https://rjonco.com/1028-9984/article/view/479913</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Lung cancer occupies a leading position in the overall structure of cancer incidence in the Krasnoyarsk Territory. Despite the positive results of the introduction of low-dose computed tomography and the current epidemiological situation caused by the new coronavirus infection COVID-19, there remains the potential to increase the detection and implementation of modern methods for the diagnosis of lung cancer.</p> <p><bold>AIM:</bold> The aim of the study was to study the incidence of lung cancer in the Krasnoyarsk Territory over the past 2012–2021 years, to build a forecast until 2030 and to search for leads in the diagnosis of this disease.</p> <p><bold>MATERIALS AND METHODS:</bold><bold> </bold>The data of the regional cancer register and the data of the Territorial Body of the Federal State Statistics Service for the Krasnoyarsk Territory were used as a source of information. We calculated the intensive indicator of lung cancer incidence in the territory of the region and predicted the incidence until 2030, using Microsoft Excel.</p> <p><bold>RESULTS:</bold> Thus, the incidence of lung cancer in the Krasnoyarsk Territory increased by 4.6%, while the female incidence increased by 31.6% and the male incidence decreased by 2.7%. Incidence rates in the region exceed those typical for the city of Krasnoyarsk for the entire period of observation. The increase in incidence in the region for the period 2012–2021 was 4.3%, and in the city — 3.1%. The male population of the region, unlike Krasnoyarsk, is characterized by a slight increase in incidence. Female morbidity increased both in the region and in the city by 23.9% and 43.3%, respectively, during the observation period. The incidence of lung cancer in the region by 2030 may amount to 54.9 per 100 thousand population and in Krasnoyarsk — 41.0 per 100 thousand population. The absence of COVID-19 would provide a higher accuracy of the forecast — 66.9 and 43.8 per 100 thousand population, respectively.</p> <p><bold>CONCLUSION:</bold><bold> </bold>Thus, over the past 10 years, an increase in lung cancer cases has been registered in the Krasnoyarsk Territory. The article provides examples of modern methods of screening and diagnosis of lung cancer, including the use of aptamers. The presented data indicates the need to improve approaches in detecting lung cancer and monitoring the effectiveness of antitumor therapy using innovative approaches.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Рак лёгких (РЛ) занимает ведущие позиции в общей структуре онкологической заболеваемости Красноярского края. Несмотря на положительные результаты внедрения низкодозной компьютерной томографии и сложившуюся эпидемиологическую ситуацию, вызванную новой коронавирусной инфекцией COVID-19, остаётся потенциал для улучшения техники обнаружения РЛ и внедрения современных методов диагностики.</p> <p><bold>Цель</bold> — анализ заболеваемости РЛ в Красноярском крае за период с 2012 по 2021 год, расчёт среднесрочного прогноза заболеваемости до 2030 года и обоснование внедрения инновационных методов ранней диагностики и мониторинга течения заболевания.</p> <p><bold>Материалы и методы. </bold>В качестве источника информации использовались данные регионального канцер-регистра и Территориального органа Федеральной службы государственной статистики по Красноярскому краю. С помощью программы Microsoft Excel произведён расчёт «грубых» показателей заболеваемости РЛ на территории края и спрогнозирована заболеваемость до 2030 года.</p> <p><bold>Результаты.</bold> За период исследования установлен рост заболеваемости РЛ в Красноярском крае на 4,6%, при этом отмечается прирост показателя женской заболеваемости РЛ на 31,6% и снижение мужской заболеваемости на 2,7%. Показатели заболеваемости в регионе превышают показатели, характерные для г. Красноярска за весь период наблюдения. Прирост заболеваемости в регионе за период 2012–2021 гг. составил 4,3%, а в городе — 3,1%. Для мужского населения региона, в отличие от г. Красноярска, характерен незначительный прирост заболеваемости. Женская заболеваемость как в регионе, так и в городе за анализируемый период увеличилась на 23,9% и 43,3% соответственно.</p> <p>Заболеваемость РЛ к 2030 году в регионе может составить 54,9 на 100 тыс. населения, а в г. Красноярске — 41,0 на 100 тыс. населения. Отсутствие COVID-19 обеспечило бы более высокую точность прогноза, и данные за период 2012–2019 гг. прогнозируют показатели заболеваемости РЛ в 2030 году для региона и г. Красноярска — 66,9 и 43,8 на 100 тыс. населения соответственно.</p> <p><bold>Заключение. </bold>Таким образом, за последние 10 лет в Красноярском крае регистрируется рост заболевших РЛ. В статье приведены примеры современных методов скрининга и диагностики РЛ, в том числе с применением аптамеров. Представленные данные свидетельствует о необходимости совершенствовать подход к выявлению РЛ и мониторинг эффективности противоопухолевой терапии с использованием инновационных подходов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>lung cancer</kwd><kwd>incidence</kwd><kwd>Krasnoyarsk</kwd><kwd>Krasnoyarsk region</kwd><kwd>screening</kwd><kwd>diagnostics</kwd><kwd>aptamers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак лёгкого</kwd><kwd>заболеваемость</kwd><kwd>г. Красноярск</kwd><kwd>Красноярский край</kwd><kwd>скрининг</kwd><kwd>диагностика</kwd><kwd>аптамеры</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Министерство здравоохранения Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Health of the Russian Federation</institution></institution-wrap></funding-source><award-id>REYC-2023-0012</award-id></award-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Министерство науки и высшего образования Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Science and Higher Education of the Russian Federation</institution></institution-wrap></funding-source><award-id>FWES-2022-0005</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters. 2023;10(1):451</mixed-citation><mixed-citation xml:lang="ru">Chhikara B.S., Parang K. Global Cancer Statistics 2022: the trends projection analysis // Chemical Biology Letters. 2023. Vol. 10, N 1. P. 451</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Global Cancer Observatory (GLOBOCAN) [Internet]. [cited 2022 Dec 12]. Available from: https://gco.iarc.fr/</mixed-citation><mixed-citation xml:lang="ru">Global Cancer Observatory (GLOBOCAN) [Internet]. [дата обращения: 12.12.2022]. Доступ по ссылке: https://gco.iarc.fr/</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225–2249. doi: 10.1002/cncr.32802</mixed-citation><mixed-citation xml:lang="ru">Henley S.J., Ward E.M., Scott S., et al. Annual report to the nation on the status of cancer, part I: National cancer statistics // Cancer. 2020. Vol. 126, N 10. P. 2225–2249. doi: 10.1002/cncr.32802</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020;76:71–76. doi: 10.1016/j.ijsu.2020.02.034</mixed-citation><mixed-citation xml:lang="ru">Sohrabi C., Alsafi Z., O’Neill N., et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) // International Journal of Surgery. 2020. Vol. 76. P. 71–76. doi: 10.1016/j.ijsu.2020.02.034</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin AD, Starinskij VV, Shahzadova AO, editors. Malignant neoplasms in Russia in 2021 (incidence and mortality). Moscow: MNIOI im. P.A. Gercena – branch of NMRRC of the Ministry of Health of Russia; 2022. (In Russ)</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва : МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin AD, Starinskij VV, Petrova GV, editors. The state of oncological care to the population of Russia in 2021. Moscow: MNIOI im. P.A. Gercena – branch of NMRRC of the Ministry of Health of Russia; 2022. (In Russ)</mixed-citation><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2021 году / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва : МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Zhuikova LD, Choynzonov EL, Ananina OA, Odintsova IN. Cancer Incidence in Siberia and Russian Far East. Siberian journal of oncology. 2019;18(6):5–11. (In Russ) doi: 10.21294/1814-4861-2019-18-6-5-11</mixed-citation><mixed-citation xml:lang="ru">Жуйкова Л.Д., Чойнзонов Е.Л., Ананина О.А., Одинцова И.Н. Онкологическая заболеваемость в Сибирском и Дальневосточном федеральных округах // Сибирский онкологический журнал. 2019. T. 18, № 6. С. 5–11. doi: 10.21294/1814-4861-2019-18-6-5-11</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Maksimova TG, Popova IN. Econometrics: educational and methodical manual. Maksimova TG, Popova IN, editors. Saint Petersburg: Universitet ITMO; 2018. (In Russ)</mixed-citation><mixed-citation xml:lang="ru">Максимова Т.Г., Попова И.Н. Эконометрика: учебно-методическое пособие / под ред. Т.Г. Максимовой, И.Н. Поповой. Санкт-Петербург : Университет ИТМО, 2018.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Merabishvili VM. The records of patients with postmortem diagnosis of cancer (population study at the federal district level). Siberian journal of oncology. 2022;21(3):5–11. (In Russ) doi: 10.21294/1814-4861-2022-21-3-5-11</mixed-citation><mixed-citation xml:lang="ru">Мерабишвили В.М. Учет больных с посмертно установленным диагнозом злокачественное новообразование (популяционное исследование на уровне федерального округа) // Сибирский онкологический журнал. 2022. Т. 21, № 3. С. 5–11. doi: 10.21294/1814-4861-2022-21-3-5-11</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Levchenko EV. Screening of lung cancer. Practical Oncology. 2010;11(2):88–95. (In Russ)</mixed-citation><mixed-citation xml:lang="ru">Левченко Е.В. Скрининг рака легкого // Практическая онкология. 2010. Т. 11, № 2. С. 88–95.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). Journal of Medical Screening. 2011;18(3):109–111. doi: 10.1258/jms.2011.011055</mixed-citation><mixed-citation xml:lang="ru">Kramer B.S., Berg C.D., Aberle D.R., Prorok P.C. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST) // Journal of Medical Screening. 2011. Vol. 18, N 3. Р. 109–111. doi: 10.1258/jms.2011.011055</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Practical recommendations for the treatment of malignant tumors of the Russian Society of Clinical Oncology [Internet]. [cited 2022 Dec 5] Available from: https://rosoncoweb.ru/standarts/RUSSCO/2022/. (In Russ)</mixed-citation><mixed-citation xml:lang="ru">Практические рекомендации по лечению злокачественных опухолей Российского общества клинической онкологии [Интернет]. [Дата обращения: 05.12.2022] Доступ по ссылке: https://rosoncoweb.ru/standarts/RUSSCO/2022/</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Zamay TN, Zamay GS, Kolovskaya OS, et al. Current and prospective protein biomarkers of lung cancer. Cancers. 2017;9(12):155. doi: 10.3390/cancers9110155</mixed-citation><mixed-citation xml:lang="ru">Zamay T.N., Zamay G.S., Kolovskaya O.S., et al. Current and prospective protein biomarkers of lung cancer // Cancers. 2017. Vol. 9, N 12. P. 155. doi: 10.3390/cancers9110155</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Prakash J, Rajamanickam K. Aptamers and their significant role in cancer therapy and diagnosis. Biomedicines. 2015;3(3):248–269. doi: 10.3390/biomedicines3030248</mixed-citation><mixed-citation xml:lang="ru">Prakash J., Rajamanickam K. Aptamers and their significant role in cancer therapy and diagnosis // Biomedicines. 2015. Vol. 3, N 3. P. 248–269. doi: 10.3390/biomedicines3030248</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang Y, Chen Y, Han D, et al. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis. 2010;2:907–918. doi: 10.4155/bio.10.46</mixed-citation><mixed-citation xml:lang="ru">Zhang Y., Chen Y., Han D., et al. Aptamers selected by cell-SELEX for application in cancer studies // Bioanalysis. 2010. Vol. 2. P. 907–918. doi: 10.4155/bio.10.46</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Wang RE, Zhang Y, Cai J, et al. Aptamer-based fluorescent biosensors. Current Medicinal Chemistry. 2011;18(27):4175–4184. doi: 10.2174/092986711797189637</mixed-citation><mixed-citation xml:lang="ru">Wang R.E., Zhang Y., Cai J., et al. Aptamer-based fluorescent biosensors // Current Medicinal Chemistry. 2011. Vol. 18, N 27. P. 4175–4184. doi: 10.2174/092986711797189637</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Ozerskaya AV, Zamay TN, Kolovskaya OS, et al. 11C-Radiolabeled Aptamer for Imaging of Tumor and Metastasis Using Positron Emission Tomography-Computed Tomography. Molecular Therapy — Nucleic Acids. 2021;26:1159–1172. doi: 10.1016/j.omtn.2021.10.020</mixed-citation><mixed-citation xml:lang="ru">Ozerskaya A.V., Zamay T.N., Kolovskaya O.S., et al. 11C-Radiolabeled Aptamer for Imaging of Tumor and Metastasis Using Positron Emission Tomography-Computed Tomography // Molecular Therapy – Nucleic Acids. 2021. Vol. 26. P. 1159–1172. doi: 10.1016/j.omtn.2021.10.020</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Zamay GS, Kolovskaya OS, Zamay TN, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Molecular Therapy. 2015;23(9):1486–1496. doi: 10.1038/mt.2015.108</mixed-citation><mixed-citation xml:lang="ru">Zamay G.S., Kolovskaya O.S., Zamay T.N., et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood // Molecular Therapy. 2015. Vol. 23, N 9. P. 1486–1496. doi: 10.1038/mt.2015.108</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Zamay GS, Ivanchenko T, Zamay TN, et al. DNA-aptamers for characterization of histological structure of lung adenocarcinoma. Molecular Therapy — Nucleic Acids. 2016;6:150–162. doi: 10.1016/j.omtn.2016.12.004</mixed-citation><mixed-citation xml:lang="ru">Zamay G.S., Ivanchenko T., Zamay T.N., et al. DNA-aptamers for characterization of histological structure of lung adenocarcinoma // Molecular Therapy - Nucleic Acids. 2016. Vol. 6. P. 150–162. doi: 10.1016/j.omtn.2016.12.004</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Zamay GS, Zamay TN, Kolovskii VA, et al. Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples. Scientific Reports. 2016;6(1). doi: 10.1038/srep34350</mixed-citation><mixed-citation xml:lang="ru">Zamay G.S., Zamay T.N., Kolovskii V.A., et al. Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples // Scientific Reports. 2016. Vol. 6, N 1. doi: 10.1038/srep34350</mixed-citation></citation-alternatives></ref></ref-list></back></article>
